A conserved protonation-dependent switch controls drug binding in the Abl kinase
Top Cited Papers
- 6 January 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (1) , 139-144
- https://doi.org/10.1073/pnas.0811223106
Abstract
In many protein kinases, a characteristic conformational change (the “DFG flip”) connects catalytically active and inactive conformations. Many kinase inhibitors—including the cancer drug imatinib—selectively target a specific DFG conformation, but the function and mechanism of the flip remain unclear. Using long molecular dynamics simulations of the Abl kinase, we visualized the DFG flip in atomic-level detail and formulated an energetic model predicting that protonation of the DFG aspartate controls the flip. Consistent with our model9s predictions, we demonstrated experimentally that the kinetics of imatinib binding to Abl kinase have a pH dependence that disappears when the DFG aspartate is mutated. Our model suggests a possible explanation for the high degree of conservation of the DFG motif: that the flip, modulated by electrostatic changes inherent to the catalytic cycle, allows the kinase to access flexible conformations facilitating nucleotide binding and release.Keywords
This publication has 53 references indexed in Scilit:
- Allosteric cooperativity in protein kinase AProceedings of the National Academy of Sciences, 2008
- On the importance of a funneled energy landscape for the assembly and regulation of multidomain Src tyrosine kinasesProceedings of the National Academy of Sciences, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Surface comparison of active and inactive protein kinases identifies a conserved activation mechanismProceedings of the National Academy of Sciences, 2006
- H++: a server for estimating pKas and adding missing hydrogens to macromoleculesNucleic Acids Research, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- A census of human cancer genesNature Reviews Cancer, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Crystal structure of the Src family tyrosine kinase HckNature, 1997
- Three-dimensional structure of the tyrosine kinase c-SrcNature, 1997